Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis

Abhilash Koratala; Xu Zeng

doi:10.1002/ccr3.1371

Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis

Clin Case Rep. 2018 Jan 4;6(2):442-443. doi: 10.1002/ccr3.1371. eCollection 2018 Feb.

Authors

Abhilash Koratala¹, Xu Zeng²

Affiliations

¹ Division of Nephrology, Hypertension and Renal Transplantation University of Florida Gainesville Florida.
² Division of Pathology, Immunology and Laboratory Medicine University of Florida Gainesville Florida.

Abstract

Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.

Keywords: Cryoglobulinemia; hepatitis C; membranoproliferative glomerulonephritis; rituximab.